Updates in Familial Hypercholesterolemia: The Future of Cholesterol Management

Boston, MA US

Saturday, April 2, 2016 | 5:45 – 8:00 AM EST
Renaissance Boston Waterfront Hotel, Pacific Ballroom

This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.

This activity is supported by an educational grant from Amgen, Inc.

SYMPOSIUM AGENDA

Opening and Welcome
Program Director: Anne C. Goldberg, MD – Washington University in St. Louis

Patient Engagement
Jonathan Karas, FH Foundation Advocate for Awareness

Genetics, Prevalence and Diagnosis of Familial Hypercholesterolemia
Ira J. Goldberg, MD – New York University

Challenges of Therapy for Familial Hypercholesterolemia: Goals, Lifestyle, Statins, Ezetimibe, Bile Acid Sequestrants and Naicin
Robert H. Eckel, MD – University of Colorado

Recent Therapeutic Advances in the Treatment of Familial Hyerpcholesterolemia: Lomitapide, Mipomersen, PCSK9 Inhibitors
P. Barton Duell, MD – Oregon Health and Science University

Moderated Panel Discussion and Audience Questions 

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with lipid disorders

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Summarize the genetic underpinnings of familial hypercholesterolemia and impact on cardiovascular outcomes
  • Evaluate strategies to optimize commonly used lipid-lowering therapies in patients with familial hypercholesterolemia
  • Describe the mechanism of action and most current information of the safety and efficacy of newer therapies to treat familial hypercholesterolemia (i.e., lomitapide, mipomersen, PCSK9 inhibitors)
  • Assess the value of newer therapies to treat patients with familial hypercholesterolemia and apply treatment

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Quality Improvement and Healthcare Delivery
General Endocrinology
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
03/25/2016
Course expires: 
04/02/2017
Event starts: 
04/02/2016 - 6:00am
Event ends: 
04/02/2016 - 8:00am
Rating: 
5
Renaissance Boston Waterfront
606 Congress Street
Boston, MA 02210
United States

Anne C Goldberg, MD, FACP, FAHA – Program Director
Associate Professor of Medicine
Washington University in St. Louis
School of Medicine
St. Louis, Missouri

Ira J. Goldberg, MD
Clarissa and Edgar Bronfman, Jr. Professor
Director, Division of Endocrinology, Diabetes and Metabolism
NYU Langone Medical Center
New York, New York

Robert H. Eckel, MD
Charles A. Boettcher Endowed Chair in Atherosclerosis
Professor of Medicine
Division of Endocrinology, Metabolism & Diabetes, and Cardiology
Professor of Physiology and Biophysics
Program Director, Adult General Clinical Research Center
University of Colorado Anschutz Medical Campus
Aurora, Colorado

P. Barton Duell, MD
Director, Lipid-Atherosclerosis Laboratory
Director, Lipid Disorders Clinic and LDL Apheresis Unit
Division of Endocrinology, Diabetes, and Clinical Nutrition
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, Oregon

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Bart Duell, MD: Consultant and Investigator, Genzyme Corporation; Consultant, Kaneka, Lilly USA, LLC; Investigator, Amgen, Ionis/ISIS, Regeneron; Research Funding, Retrophin; Speaker, Sanofi
Robert Eckel, MD: Advisory Board, Consultant and Grant Support: ISIS Pharmaceuticals; Advisory Board and Consultant, Janssen Pharmaceuticals, Regeneron/Sanofi; Grant Support, UniQure
Anne Goldberg, MD: Advisory Board Member, Consultant, and Research Funding, Regeneron, Sanofi-Aventis; Consultant, AstraZeneca, uniQuire; Editor, Merck & Co., Inc. Manual of Diagnosis and Therapy; Research Funding, Amarin Pharma, Inc., Amgen, Genzyme, Glaxo-Smith-Kline, Isis Pharmaceuticals, Merck & Co., Inc., Pfizer
Ira Goldberg, MD: Research Support, Bristol-Myers Squibb, ISIS, Janssen

The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation

Accreditation Period

Course opens: 
03/25/2016
Course expires: 
04/02/2017